Skip to Main Content

​YCCI & the Yale Cultural Ambassadors host: "COVID Community Connection: What You Need to Know About the Vaccine and COVID-19"

March 05, 2021

​YCCI & the Yale Cultural Ambassadors host: "COVID Community Connection: What You Need to Know About the Vaccine and COVID-19"

 .
  • 00:00Good evening everyone.
  • 00:02Welcome to our webinar tonight.
  • 00:04We are thrilled to have all of you here.
  • 00:09We are thrilled to have this a steam
  • 00:12group of experts to help us understand
  • 00:15some of the issues surrounding Kovit
  • 00:19and HealthEquity and our vaccines.
  • 00:21And I wanted to start by letting
  • 00:25everyone know that this event is in
  • 00:28will be available in Closed caption.
  • 00:31Anne in Spanish and right now
  • 00:34I'm going to ask Rebecca Lillian,
  • 00:37our Technical Support coordinator,
  • 00:38to just Flash a slide that will
  • 00:41show everyone how to select their
  • 00:44language and their preferences.
  • 00:46Rebecca, if you could share
  • 00:48your screen for us.
  • 00:54So these are the.
  • 00:56These are the instructions if you
  • 00:58need technical assistance you can just
  • 01:00type your message in the Q&A box.
  • 01:03Or if you're watching us on Facebook Live,
  • 01:06you can also message the team the
  • 01:08support team in Facebook Live.
  • 01:14Thank you Rebecca.
  • 01:17Now I'm going to turn it over to
  • 01:20Dean Brown to get us started.
  • 01:23Dane Brown. Thank you so much tiesha.
  • 01:25I'm Nancy Brown.
  • 01:26I'm the Dean of the Yale School
  • 01:29of Medicine and we're very pleased
  • 01:31that you were here with us tonight.
  • 01:34They remember many members of our School of
  • 01:37Medicine community including Yale Medicine,
  • 01:39YCC, Iyanar, Yelsey, TSA,
  • 01:40Eric, our partner, Yale,
  • 01:42New Haven Health System,
  • 01:43and we're particularly pleased
  • 01:45that the cultural Ambassadors
  • 01:47are hosting this town Hall.
  • 01:49In joining along with the
  • 01:50other members of our panel,
  • 01:52including a special guest from the FDA.
  • 01:56The impact of COVID-19 over the
  • 01:58last year has been devastating.
  • 02:01In the US alone,
  • 02:03we've had approximately 28 million
  • 02:06cases and more than 500,000 Americans
  • 02:09have succumbed to the disease.
  • 02:12The impact has not been equal.
  • 02:14Black and Brown Americans have been
  • 02:17disproportionately impacted with black
  • 02:19or African Americans and Hispanics.
  • 02:21Three times more likely to
  • 02:23be hospitalised and twice as
  • 02:26likely to die from the disease.
  • 02:29Today vaccines provide us with
  • 02:32hope that we can overcome covid.
  • 02:35But we also understand that there
  • 02:37are concerns about vaccines,
  • 02:39and so we have invited a distinguished
  • 02:42panel of guests tonight to provide
  • 02:44information and to address some of the
  • 02:47uncertainties and fears of our communities.
  • 02:50Tonight I'll begin with some
  • 02:52brief introductions of those
  • 02:54from whom you will hear.
  • 02:56But we will leave lots of time
  • 02:59for discussion and questions.
  • 03:02You asked the question, please use the
  • 03:04Q&A function from your zoom.
  • 03:06We also have questions that
  • 03:09were submitted ahead of time.
  • 03:11That we will begin with.
  • 03:13So let me begin by introducing our panel.
  • 03:17I'm delighted to introduce
  • 03:18Rear Admiral Sharde Rojo,
  • 03:20who is the Associate Commissioner
  • 03:22for Minority Health and director
  • 03:24of the Office of Minority Health
  • 03:27and HealthEquity in the Office of
  • 03:29the Commissioner at the US Food and
  • 03:32Drug Administration and Admiral
  • 03:33Rojo will tell us a little bit
  • 03:36more about that role in a moment.
  • 03:40Also with us tonight. His doctor
  • 03:43Marcella Nunez Smith who is the
  • 03:46associate Dean of
  • 03:47HealthEquity Research at Yale
  • 03:48School of Medicine and Deputy Director of
  • 03:51the Yale Center for Clinical
  • 03:53Investigation, or as we call it, YCCI
  • 03:56She is the founding director of Equity
  • 03:59Research and Innovation Center or
  • 04:00Eric. The director of the Center for
  • 04:03Research, Engagement, director of the
  • 04:05Pozen Commonwealth Fund Fellowship
  • 04:07in HealthEquity Leadership and Co.
  • 04:08Director of the Doris Duke
  • 04:10Clinical Research Fellowship.
  • 04:13Doctor Nina Smith currently serves
  • 04:15as senior adviser to the White House
  • 04:18COVID-19 response team and chair of the
  • 04:20COVID-19 HealthEquity Task Force at the
  • 04:23Department of Health and Human Services.
  • 04:28We have Doctor Tom Ball sack,
  • 04:30Chief Medical Officer and
  • 04:31senior Vice president of the
  • 04:34Yale New Haven health system.
  • 04:36Tom is also associate clinical
  • 04:38Professor of medicine and
  • 04:39lecturer in public Health,
  • 04:40as well as fellow of the American
  • 04:42College of Healthcare Executives in the
  • 04:44American Board of Internal Medicine.
  • 04:48We have Doctor Alan show,
  • 04:50chief medical information,
  • 04:51Officer of the Yale School
  • 04:53of Medicine and Yale,
  • 04:54New Haven Health and Co.
  • 04:56Director of Informatics for YCC I.
  • 05:00In his role, Doctor Shah leads a team
  • 05:03of physician Informaticians who are
  • 05:04responsible for medical
  • 05:06leadership of a health
  • 05:07electronic record system.
  • 05:08And support technology systems to
  • 05:10provide clinical decision support
  • 05:12and innovation needed to deliver
  • 05:14the best possible health care.
  • 05:18Next, I'd like to introduce
  • 05:19Doctor Onama Oblog who who is
  • 05:22associate Professor of Medicine
  • 05:24and program director infectious
  • 05:25diseases in the School of Medicine.
  • 05:30The last five years.
  • 05:32He has been
  • 05:33the director of the Yale AIDS Program
  • 05:36in the HIV Clinical Trials Program
  • 05:39and a principal direct investigator
  • 05:41on numerous pharmacokinetic phase two
  • 05:44and three safety and efficacy trials
  • 05:47of novel antiviral compounds for HIV.
  • 05:49But during the Kovid pandemic,
  • 05:52he has been the principal investigator
  • 05:54on many investigational therapeutic and
  • 05:57preventive clinical trials for COVID-19.
  • 06:00Including the Pfizer Bio
  • 06:02Intec vaccine trial.
  • 06:06Teacher Harris, whom you've already
  • 06:08met, is deputy Director and Chief
  • 06:10Operating Officer for the Yale
  • 06:12Center for Clinical Investigation.
  • 06:14And the director for clinical
  • 06:16research for Yale School of Medicine.
  • 06:19She sits on the external scientific
  • 06:21advisory boards for CT essays at New York,
  • 06:24Washington and Rockefeller Universities.
  • 06:26the University of Buffalo, Colorado,
  • 06:28Florida, Rochester in Washington
  • 06:30and at University College London.
  • 06:32Hospitals for Biomedical Research Center.
  • 06:37Reverend Elvin Clayton is the
  • 06:40pastor of Walters Memorial a Me
  • 06:42Zion Church in Bridgeport, CT.
  • 06:46A native of Waterbury, CT,
  • 06:48he attended the local schools
  • 06:50and graduated from the WF Raynor
  • 06:52Regional Technical Vocational School,
  • 06:54but I did not know until tonight
  • 06:56is that Reverend Clayton worked in
  • 06:59the automotive refinishing business
  • 07:00for 25 years before beginning
  • 07:03his pastoral vocation in 1983.
  • 07:05After years of a passionate pursuit of music.
  • 07:09Reverend Clayton became
  • 07:10a cultural ambassador more than 11
  • 07:12years ago so that he could help
  • 07:15raise awareness of the importance of
  • 07:18clinical trials for his community.
  • 07:20He says the program has taught him the
  • 07:22importance of diversity among clinical
  • 07:24trial participants to include people
  • 07:26from different ethnic backgrounds
  • 07:28as well as women and children.
  • 07:30Reverend Doctor
  • 07:31Leroy Opari Junior is the
  • 07:33pastor of Saint Stephens AME
  • 07:36Ezion Church in Branford, CT.
  • 07:39Reverend Perry earned his
  • 07:41BA from Livingstone College,
  • 07:43his mdev from Yale Divinity,
  • 07:45STM and doctoral degree from New York
  • 07:49Theological Seminary in New York.
  • 07:51He remarks that although he was
  • 07:53not aware that he was aware of
  • 07:55health care disparities before
  • 07:57becoming a cultural ambassador,
  • 07:58he was not aware of the clinical
  • 08:00research being conducted at Yale.
  • 08:02And like Reverend Clayton,
  • 08:03Doctor Perry has been a cultural
  • 08:06ambassador for more than 11 years.
  • 08:08He serves as an advocate within
  • 08:10the African American community,
  • 08:11in particular, and the larger
  • 08:14minority communities in general.
  • 08:16I'd like to thank all of our
  • 08:19panelists for joining us tonight
  • 08:21and now begin with a few questions.
  • 08:24Money on this one is for you.
  • 08:27We know that there are many concerns
  • 08:29surrounding the COVID-19 vaccine,
  • 08:31and especially for communities of color.
  • 08:34Could you please give us some
  • 08:36background on the essence of how the
  • 08:39currently approved vaccines work?
  • 08:42And thank you very much.
  • 08:43Jim Brown and Nice to see everyone and
  • 08:46thanks all of you for joining on on
  • 08:48various platforms so you know can we
  • 08:50just step back and think about just
  • 08:52how amazing it is that in a shorter
  • 08:55short period of time that we have,
  • 08:57you know really highly effective
  • 08:58unsafe vaccines.
  • 08:59I think if you you know hold all of us at,
  • 09:02you know a year ago as to our
  • 09:04optimism about it happening,
  • 09:06I think many of us may have been
  • 09:08not too sure that this would be so.
  • 09:10I think this is really about.
  • 09:12Best outcome,
  • 09:13and I think it's it's worth
  • 09:15celebrating just the efforts and
  • 09:18collaborations that related to
  • 09:19these really landmark lifesaving.
  • 09:22You know, achievements in regards
  • 09:24that just to clarify again,
  • 09:26the vaccines have received
  • 09:28emergency use authorization.
  • 09:29There still haven't received full approval,
  • 09:32but that's a mechanism that
  • 09:34allowed in a pandemic setting to
  • 09:37be able to allow people access to
  • 09:40vaccine candidates that have been.
  • 09:46So I would focus on the current
  • 09:48vaccines that are currently authorized
  • 09:51for use in the United States.
  • 09:53There's a vast array of different
  • 09:56vaccine approaches that have
  • 09:58been used converging frankly or.
  • 10:00The vaccine antigen or the target?
  • 10:02I think we've all benefited from
  • 10:04the knowledge of the life cycle of
  • 10:07the virus so very early on it was
  • 10:09pretty clear what everyone should
  • 10:11target in the virus to be able to
  • 10:14prevent an infection from taking hold.
  • 10:16And that was the spike protein and
  • 10:18so you know all the vaccine more
  • 10:21majority of the vaccine approaches
  • 10:22have really focused on helping
  • 10:24the human body produces immune
  • 10:26immunity against this by quoting.
  • 10:28To really prevent that first step.
  • 10:30That the virus takes 2 to be
  • 10:33able to cause an infection.
  • 10:35The two platforms that we have
  • 10:37currently authorized in the US are
  • 10:39the Messenger RNA vaccines as well
  • 10:41as the viral that their vaccine
  • 10:44so the Messenger RNA vaccines are
  • 10:46the Pfizer maternal vaccines,
  • 10:47which were the lead in you know
  • 10:50more advanced stage vaccines that
  • 10:52received authorization and we know
  • 10:54just last weekend that we're very
  • 10:56proud that the FDA greenlighted,
  • 10:58the Johnson and Johnson vaccine for use.
  • 11:01You know each of them has their
  • 11:03own unique advantages,
  • 11:05and in some cases just unique
  • 11:07considerations around.
  • 11:08You know safety, efficacy,
  • 11:09storage requirements, etc.
  • 11:10You know how they work.
  • 11:12The Messenger RNA vaccines marinese
  • 11:14genetic code for the spike protein,
  • 11:17so once it gets into the body,
  • 11:19the body reads it off,
  • 11:21produces the spike protein is
  • 11:23presented to the immune system,
  • 11:25and that's how individuals
  • 11:27develop immunity to that.
  • 11:28Messenger RNA vaccines are knew too.
  • 11:31Yeah,
  • 11:31approval or authorization for human use,
  • 11:34but the technology has really been
  • 11:36percolating for over two decades,
  • 11:38including studies in animals.
  • 11:40And looking at that technology.
  • 11:42So that's just to debunk some of the
  • 11:45concerns as to it being really brand new.
  • 11:48You know, a technology.
  • 11:50It's really been percolating for awhile,
  • 11:52but truly applied to human
  • 11:54disease in advanced stages.
  • 11:56More recently,
  • 11:57the viral vector vaccines typically
  • 11:59use a platform of viruses that.
  • 12:02There are tweaked to prevent
  • 12:04them from causing human disease,
  • 12:06so there are tweaks or they don't replicate.
  • 12:09They typically the parts of the virus
  • 12:11that can cause disease are also tweaked
  • 12:14as well so that they tend not there.
  • 12:17They are not expected to cause disease,
  • 12:19but they just really used as vectors or
  • 12:22vehicles or carry generate material.
  • 12:24So the viral vectors are tweaked to
  • 12:26introduce the genetic material for that
  • 12:29includes for the spike protein as well,
  • 12:31and so once the vaccine is prepared
  • 12:33and administered to individuals.
  • 12:35You know, again,
  • 12:36that genetic material is read off
  • 12:38then despite protein is eventually
  • 12:40produced through series of steps and
  • 12:42that also triggers immune system.
  • 12:44So the science behind the vaccines
  • 12:46have been sound and it's been
  • 12:48great to really see two relatively
  • 12:50novel at technologies, Messenger,
  • 12:51RNA and viral vectors really come
  • 12:54to the four of being the 1st
  • 12:56wave of vaccines that have been
  • 12:58approved.
  • 12:59Now here's some really awesome news.
  • 13:01So these vaccines are really effective.
  • 13:03You know, we found that the Messenger
  • 13:05RNA vaccines were 9495% effective.
  • 13:07In preventing again,
  • 13:08I think in the introduction I talked
  • 13:10about what our guesses could have been.
  • 13:13I think we'd all have been satisfied
  • 13:15with anything that was about 50% frankly,
  • 13:18and 95% is just, you know,
  • 13:19as good as it gets with preventing
  • 13:21a symptomatic COVID-19 disease.
  • 13:23We saw that the Johnson and Johnson
  • 13:26vaccine differs a little bit from
  • 13:28the Pfizer maternal vaccines because
  • 13:29it's a single shots and vaccine.
  • 13:31Two dose vaccine is being evaluated,
  • 13:34but the data we have is for the single
  • 13:36shot vaccine and also showed about a 66%.
  • 13:39Efficacy now I want to make something clear,
  • 13:42like in spite of the different numbers.
  • 13:45I think the great thing about the
  • 13:47current authorized vaccines are that
  • 13:49they are really highly effective
  • 13:51in preventing severe and critical
  • 13:52illness from COVID-19 as well as
  • 13:55debt uniformly across the board
  • 13:56regardless of the type of vaccine.
  • 13:58That's amazing so that you could almost
  • 14:00say that a clinical trial data strongly
  • 14:03suggests that if you get vaccinated
  • 14:05with any of these vaccine platforms,
  • 14:07that the chance of you having severe disease.
  • 14:10Being hospitalised going to the ICU,
  • 14:12being ventilated and dying
  • 14:14are really negligible,
  • 14:15and that's really worth celebrating.
  • 14:17Now let's put some icing on the cake.
  • 14:19The safety profiles of these vaccines
  • 14:21have been just beyond amazing,
  • 14:23and we're seeing that now that the vaccines
  • 14:26have been rolled out to larger populations
  • 14:28that those findings are holding up.
  • 14:30I mean,
  • 14:31in the clinical trials,
  • 14:33we did not find any serious adverse events
  • 14:35or we're talking about things that the
  • 14:37vaccine causes that will lead to unexpected
  • 14:40hospitalization or unintended death.
  • 14:42Which is just again beyond amazing and
  • 14:43I think as the rollout has occurred,
  • 14:46we've we've all been witnesses.
  • 14:47You know,
  • 14:48many of us on the panel have
  • 14:49taken the vaccines ourselves,
  • 14:51and we know that they've really been safe.
  • 14:53The last point I just want to make is,
  • 14:56of course,
  • 14:56now that we have highly effective vaccines.
  • 14:58The question is,
  • 14:59how can we make the best of it?
  • 15:01And so you know,
  • 15:02translating vaccine efficacy
  • 15:03to real world effectiveness.
  • 15:05So there are people on the panel
  • 15:06who are way more better than me
  • 15:08with being able to explain some of
  • 15:11the issues around hesitancy and.
  • 15:12Uptick,
  • 15:13but one point I just wanted to
  • 15:15make is that one of the goals of
  • 15:17the rollout of the vaccines is
  • 15:19for us to achieve herd immunity,
  • 15:21and that is if we have sufficient
  • 15:23numbers of people in the Community
  • 15:25who are vaccinated,
  • 15:26developed immunity either through
  • 15:28vaccination and of course in
  • 15:29minority through immunity generated
  • 15:30from having the disease itself.
  • 15:32So a composite of that that if we
  • 15:34have enough percent of people,
  • 15:36you know estimates or anything
  • 15:38from 65 to 85%.
  • 15:39Roughly,
  • 15:39there are lots of things that
  • 15:41move the bar along that number.
  • 15:43But if we have enough people vaccinated
  • 15:45that we're able to really impact the
  • 15:47ability of the disease to continue
  • 15:49to circulate within our communities.
  • 15:50So this is by way of introduction,
  • 15:52and I'm sure we'll have
  • 15:54time to address questions.
  • 15:56Thank you very much.
  • 15:58Doctor Nunes Smith. We we opened by.
  • 16:02With the realization that people
  • 16:05in communities of color are
  • 16:07more than twice as likely to
  • 16:09die of covid than white people,
  • 16:12but minority Americans are
  • 16:14receiving vaccines at lower rates
  • 16:16than their white counterparts,
  • 16:18are there impediments to
  • 16:19equitable vaccine distribution?
  • 16:21And what are they?
  • 16:24Thank you Dean Brown and let me just
  • 16:26just add my my gratitude to be here in
  • 16:30this conversation with everyone tonight
  • 16:32and to thank everybody for for joining.
  • 16:35Um? You know, these are hard statistics
  • 16:39and and it still causes me great
  • 16:42pause every time I hear the frame.
  • 16:45And I worry sometimes that we
  • 16:47become numb to the statistics and.
  • 16:51We forget that we have lost our
  • 16:53family members and, you know,
  • 16:55we've lost our uncles and our friends,
  • 16:58our neighbors,
  • 16:59our coworkers families are grieving.
  • 17:01Communities are suffering.
  • 17:02We've lost all this potential,
  • 17:04and so less less.
  • 17:05We forget that I wanted to
  • 17:08be sure to honor you, know,
  • 17:10the over half a million lives that we've
  • 17:14now lost to COVID-19 in this country.
  • 17:17And when we when we talk about the
  • 17:20pandemic to your absolute point,
  • 17:23the the impact has has been
  • 17:25uneven and we see communities
  • 17:27of color among the hardest hit.
  • 17:30When we think about no cases as well
  • 17:35as hospitalizations as well as death.
  • 17:38And well, as economic suffering.
  • 17:41So you know the promise of the vaccine.
  • 17:43You know that?
  • 17:44Let me take us to a hopeful place, right?
  • 17:47I am very optimistic about the
  • 17:49scientific discovery we just heard about.
  • 17:51It is tremendous to have three
  • 17:53condom right 123 and it is fantastic.
  • 17:56And so we all need to be able to
  • 17:58take advantage of the vaccine
  • 18:00development in order to get to
  • 18:02the other side of this pandemic.
  • 18:04So it is the absolute right question to say.
  • 18:07Where are we now with that and,
  • 18:09and how might we?
  • 18:11Do better moving forward so.
  • 18:13You know the the data we have.
  • 18:16Let me start there and make that point
  • 18:18as far as who is getting vaccinated
  • 18:20are incomplete and so you know for
  • 18:23about 50% of vaccinations in this
  • 18:25country we have race ethnicity data.
  • 18:28So, so inadequate,
  • 18:29but I would say that despite
  • 18:31the data challenges,
  • 18:33the early patterns have clearly
  • 18:34emerged and we see that black
  • 18:37and Brown individuals are getting
  • 18:39vaccinated at rates lower than the
  • 18:41share we would expect given their
  • 18:44representation in the general population,
  • 18:46and so that is concerning.
  • 18:48You know,
  • 18:48some of these data again early on,
  • 18:51and we can have conversations
  • 18:53about eligibility and priority,
  • 18:55but I think you know we have to fundamentally
  • 18:58in a conversation about vaccine confidence.
  • 19:01Also, talk about vaccine access
  • 19:03that has to be easy,
  • 19:05right?
  • 19:05Vaccination has to be convenient so we know.
  • 19:08For example,
  • 19:09vaccinations are free,
  • 19:10so that's an important first step,
  • 19:12but I'm sure if we opened up the mikes now,
  • 19:16we could hear people stories
  • 19:18around things like registration
  • 19:19aware some of those challenges,
  • 19:21other structural barriers that might exist,
  • 19:23things like transportation not
  • 19:25having access to paid time off,
  • 19:27potentially right, and so.
  • 19:28You know those I think are some
  • 19:31of the considerations from the
  • 19:33federal administration standpoint.
  • 19:35It has been top of mind to be
  • 19:38sure that we are ahead on access,
  • 19:40and so launching several programs in
  • 19:43the first three weeks really based on
  • 19:46making sure that when people are at yes
  • 19:49another part of our conversation is sort
  • 19:51of all that is involved in folks be able
  • 19:54to make that decision for themselves.
  • 19:57But when people are at yes. And they are.
  • 20:00So they have to connect with Maxine
  • 20:02and so just a couple of examples
  • 20:04of some of the programs that we've
  • 20:06launched people may have seen the
  • 20:09Community vaccination centers, right?
  • 20:10Some of those are mass vaccination sites,
  • 20:12but really and truly they come
  • 20:14in different flavors and sizes,
  • 20:15and so you'll see some of those
  • 20:18vaccination centers in school gyms, right?
  • 20:19In neighborhoods and communities.
  • 20:21Many of those vaccination centers
  • 20:22also have mobile capacity, right?
  • 20:24Right now we see.
  • 20:25I'll use the phrase my colleague
  • 20:27Andy Slavitt uses right now we
  • 20:29see people chasing vaccines.
  • 20:30That's what's happening.
  • 20:31Everybody sitting with eight
  • 20:32computers and refreshing and.
  • 20:34People are chasing that sees
  • 20:35but pretty soon vaccines.
  • 20:37They're going to find people
  • 20:38right and so things like mobile
  • 20:40units that can get us deep into
  • 20:43communities are going to be critical.
  • 20:45We've expanded and launched
  • 20:46a retail pharmacy program,
  • 20:47including local pharmacies,
  • 20:49independent pharmacies as well.
  • 20:50We are aware that there are pharmacy
  • 20:52deserts in this country right?
  • 20:5490% of Americans live within
  • 20:565 miles of a pharmacy.
  • 20:57If you don't have a car
  • 20:59there 5 miles is not easy,
  • 21:01so we are accounting for that as well.
  • 21:04We're partnering with fairly
  • 21:05qualified community health centers.
  • 21:06All of these.
  • 21:07All of these initiatives are about getting
  • 21:09direct federal doses to these sites alright,
  • 21:12and making sure that we're putting
  • 21:14the sites where they are most needed.
  • 21:16Using metrics like the Social
  • 21:18Vulnerability Index from the CDC to say,
  • 21:20how do we make sure?
  • 21:21That when people are ready,
  • 21:23their vaccine is nearby.
  • 21:24It is close,
  • 21:25it is accessible,
  • 21:25so I think it's the right question
  • 21:27to think and make sure I lead
  • 21:29with access and addressing.
  • 21:30Many of these structural
  • 21:31barriers and concerns,
  • 21:32and I'm sure we're going to unpack
  • 21:34and talk more about tonight.
  • 21:36Great, thank you.
  • 21:39Admiral Rojo,
  • 21:40you are
  • 21:41the director of the FDA Office of
  • 21:43Minority Health and HealthEquity.
  • 21:45Can you give us a little bit of background
  • 21:48on that office and its mission?
  • 21:53Sure, first I want to say of course,
  • 21:55thank you Dean Brown and thank you to
  • 21:57the Yale Coach Ambassadors for the
  • 21:59opportunity to participate and good
  • 22:01evening everyone is truly a pleasure
  • 22:03to be a part of the conversation this
  • 22:05evening and I'm going to take a step a
  • 22:08little bit back 'cause we many of you
  • 22:10are probably very familiar with FDA,
  • 22:12but just to give you a little bit
  • 22:14of background about FDA and our
  • 22:16mission and what we do,
  • 22:18so FDA is responsible for protecting
  • 22:19public health by are sharing the safety,
  • 22:22efficacy and security of the Ranger.
  • 22:23Product that we regulate.
  • 22:25And of course you just heard about
  • 22:27one of those product vaccines
  • 22:28extremely important in our agency.
  • 22:30We have an office of Minority Health
  • 22:33and HealthEquity and I think it's
  • 22:34important to know that we have an office
  • 22:37that's dedicated to advancing the health
  • 22:39of racial and ethnic minority populations.
  • 22:41So our office was established at FDA in 2010.
  • 22:44We were originally established
  • 22:45as the Office of Minority Health.
  • 22:47We are now of course named the Office
  • 22:50of Minority Health and HealthEquity
  • 22:51and we work to protect and promote the
  • 22:54health of racial and ethnic minority.
  • 22:56An other other,
  • 22:57under under represented populations.
  • 22:59By focusing our efforts really in two
  • 23:01key areas and that's research and
  • 23:03outreach in communication that works,
  • 23:05shorts addressing, health disparities.
  • 23:07Of course,
  • 23:07we work broadly across our agency.
  • 23:09We work very closely with
  • 23:11our centers and offices,
  • 23:13and we also work really closely with
  • 23:15public and private sector stakeholders.
  • 23:17I mentioned that we focus our
  • 23:19work in two areas.
  • 23:21So,
  • 23:21for example,
  • 23:22we have a research and collaboration
  • 23:24program where we aim to advance
  • 23:26minority health and health.
  • 23:27Equity focused research,
  • 23:28which is so critical.
  • 23:30We just heard about the need for data and
  • 23:33that's one of our key priorities as well.
  • 23:35We support intramural extramural research.
  • 23:37We participate in research opportunities
  • 23:39across our agency and another area
  • 23:41that's really important for us is
  • 23:42making sure that we offer opportunities
  • 23:44for internships and fellowships.
  • 23:46We want to be able to continue to provide
  • 23:48training in the face of health disparities.
  • 23:51And of course,
  • 23:52we work very closely with a range of
  • 23:54stakeholders to advance our research agenda.
  • 23:56The other area that I mentioned,
  • 23:58we focus on everything.
  • 24:00Communication,
  • 24:00so we aim to improve decades communications
  • 24:03with the populations that we serve.
  • 24:05And we do that through a range of both
  • 24:07culturally and linguistically tailored
  • 24:09programs, initiatives and campaigns.
  • 24:10Probably our most notable campaign is our
  • 24:13diversity in clinical trials initiative,
  • 24:15which is a key priority for
  • 24:17our office as well as FDA,
  • 24:19we develop health education materials
  • 24:20we engage in social media outreach.
  • 24:22We really want to make sure that
  • 24:24we had a diverse means to reach
  • 24:27our diverse consumers.
  • 24:28We have a website we have.
  • 24:30My HealthEquity lecture series,
  • 24:32where we bring experts in the space
  • 24:34of minority health and HealthEquity
  • 24:35to share that information.
  • 24:37Really,
  • 24:37not only with FDA staff but also with the
  • 24:40public in one area that's
  • 24:42also very important for us,
  • 24:43and I think that this is important across
  • 24:46all of the work that we do in the office.
  • 24:49Is collaborations and partnerships.
  • 24:50Anyone that works in the
  • 24:52space of health disparities?
  • 24:53We all know that we cannot
  • 24:55achieve this alone,
  • 24:56and it's critically important that
  • 24:58we work together so collaborations
  • 24:59and partnerships are very important
  • 25:01for us to achieve our mission.
  • 25:03And one of those partnerships is of course
  • 25:06the opportunity for us to work with Yale.
  • 25:08We have a memorandum of understanding
  • 25:10with Yale University which provides an
  • 25:12opportunity for us to engage with the
  • 25:14Yellow Cultural Ambassador program,
  • 25:15which has been so important for us
  • 25:17as we continue to work to advance
  • 25:20diversity in clinical trials.
  • 25:21We've also had the opportunity
  • 25:22to engage on various different
  • 25:24scientific collaborations,
  • 25:25different types of outreach
  • 25:26and educational initiatives,
  • 25:27as well as, of course,
  • 25:29having the opportunity for Yale
  • 25:30interns to rotate through our office.
  • 25:32We've had a couple that have had the
  • 25:35opportunity to rotate through our office, so.
  • 25:37Again,
  • 25:38collaborations and partnerships
  • 25:39are so very important to us.
  • 25:42So I'll start there.
  • 25:43Stop there.
  • 25:44I can keep going
  • 25:45on and on, but I'll pause there.
  • 25:46That's wonderful and it's A wonderful Q
  • 25:49for me to turn to teacher Harris to say.
  • 25:521st, If you would explain iccy and
  • 25:57I'm also interested in hearing.
  • 26:00There is mistrust based on
  • 26:02past research experience,
  • 26:03and I wonder if you could talk
  • 26:05a little bit about that history
  • 26:07and so I'll turn it over to you.
  • 26:11Thank you Dean Brown and thank you
  • 26:14everyone for joining us and thank you,
  • 26:16Arsene panelists.
  • 26:17We greatly appreciate you being here
  • 26:20to share the knowledge with everyone.
  • 26:22The Yale Center for Clinical Investigation
  • 26:24is really the the unit within the School
  • 26:28of Medicine within our health system.
  • 26:30Within our University that's charged
  • 26:32with facilitating the research
  • 26:34behind the scenes making sure
  • 26:36that we have the systems in place,
  • 26:38making sure that we have the
  • 26:41locations in place making sure
  • 26:43that we have the electronic tools.
  • 26:46To have our clinical research
  • 26:48not only run efficiently,
  • 26:49but thinking about it from
  • 26:51a patient centric POV,
  • 26:53making sure that all of our patients
  • 26:55and our community have access to the
  • 26:59most innovative of clinical trials
  • 27:01opportunities and so that's really
  • 27:03what the the center is is about.
  • 27:05And it's we have the wonderful
  • 27:08support of NIH,
  • 27:09an RCT SA grant which provides for
  • 27:11a lot of that infrastructure and
  • 27:14helps to support those activities,
  • 27:16both locally.
  • 27:17But it also helps us make national
  • 27:19connection so that we can partner
  • 27:22with other institutions to share best
  • 27:24practices and to make the research
  • 27:26environment that supports and underpins
  • 27:28all of the clinical and translation
  • 27:31and research that happens in the US.
  • 27:33And even with international partnership.
  • 27:35So those have been important
  • 27:37components of what we do,
  • 27:39and the center was founded in 2005,
  • 27:41so we've been around for quite some time.
  • 27:45One of the most important
  • 27:47missions that we have,
  • 27:48and it's LED us to the incredible
  • 27:50partnership with the FDA Office of
  • 27:52Minority Health and HealthEquity and
  • 27:54many other wonderful partnerships.
  • 27:56But one of the most important things.
  • 27:59I think that we've done as a center
  • 28:01was to connect with our community
  • 28:04with our cultural ambassadors
  • 28:06and that was about 10 years ago.
  • 28:08And the reason that we connected with
  • 28:11the cultural ambassadors was we were
  • 28:14looking across our research enterprise.
  • 28:16And and like much of the rest of the
  • 28:19country and the rest of the world,
  • 28:21troubled by the lack of minority
  • 28:23participation in clinical research.
  • 28:25And So what we did as a result we
  • 28:27we tried to understand what some of
  • 28:30those issues and those barriers were.
  • 28:33Two participation and what we
  • 28:35found was that there was a lot
  • 28:37of it was related to trust,
  • 28:39and not only the trust of sort of the
  • 28:43past abuse is in research, but also.
  • 28:45A lack of understanding of clinical research.
  • 28:48What it means,
  • 28:50what an informed consent is,
  • 28:52what even the the fact that the
  • 28:55clinical research opportunity existed.
  • 28:57And so through the partnership
  • 28:59with the ambassadors,
  • 29:00what we've done is really try to spread
  • 29:03the message that it's it's really
  • 29:06important to acknowledge that those
  • 29:08past issues did happen in research.
  • 29:11Tuskegee did happen,
  • 29:12Henrietta lacks that happened,
  • 29:14but one of the really important messages
  • 29:17is that regulatory change happened
  • 29:19as result of those mistrust that
  • 29:22there is additional safety protocols
  • 29:24that are put in place to make sure.
  • 29:28That individuals are protected
  • 29:29that we have IRB process,
  • 29:32an institutional review process
  • 29:33where all of the research is reviewed
  • 29:36and that review is mandated to
  • 29:38have a community representative.
  • 29:40And so there are things that
  • 29:43are really important for the
  • 29:45general community to know about.
  • 29:47You know, again,
  • 29:48acknowledging that these past issues
  • 29:51did happen in these in research that
  • 29:54there are these past mistrust but also
  • 29:56to make sure that there's awareness.
  • 29:59Of what has he?
  • 30:00Open and what the protections
  • 30:02truly are that exists in research
  • 30:04and the partnership with the
  • 30:06ambassadors became key to that,
  • 30:08because what we found was that our
  • 30:11community wanted to hear from voices
  • 30:13that they trusted and that might not
  • 30:16have been at the time or even now,
  • 30:18the health profession,
  • 30:19and so part of the role the ambassadors
  • 30:22have played that so critical is to
  • 30:24gain the knowledge for themselves,
  • 30:26to understand all of these very complex
  • 30:29research issues and then to help
  • 30:31carry the message to their community.
  • 30:34And make sure that the community
  • 30:36members understand and can ask their
  • 30:38questions and can ask those questions
  • 30:41of of someone that they already
  • 30:43have a trust relationship with.
  • 30:45And so we formed this partnership with
  • 30:48the Amy Zion Churches, African Methodist,
  • 30:50Episcopal, Zion churches.
  • 30:51I'll try not to use acronyms to this evening,
  • 30:55but the IME Zion Churches of Connecticut,
  • 30:58Anheuser for progressive action
  • 30:59and we have just been astounded.
  • 31:02Our partners are amazing.
  • 31:03And they help us be better every day,
  • 31:06and I definitely won't try to
  • 31:08speak on their behalf because I
  • 31:10will do a very poor job.
  • 31:12I will let you hear from
  • 31:13the experts themselves.
  • 31:16Thank you Reverend Perry,
  • 31:18I wonder if I might turn to you and.
  • 31:24I believe you've participated in some trials,
  • 31:27including a kovid vaccine trial.
  • 31:28Can you share a little bit
  • 31:31about your experience?
  • 31:43Reverend Perry, I believe
  • 31:44you're on mute still.
  • 31:4730 There we go.
  • 31:50OK, I was just saying thank you I gave.
  • 31:52I just gave my speech but I
  • 31:54guess I'll have to repeat it.
  • 32:01The our work as cultural ambassadors
  • 32:03has let us in a lot of directions
  • 32:06and recently ribbon Clayton and I
  • 32:09did take part in the Pfizer study.
  • 32:11And part of the reason that we took.
  • 32:15Part in this study was to say to our
  • 32:18communities that we thought this was
  • 32:20an important step for all of us.
  • 32:23And we wanted to show and have them see
  • 32:25that we believed enough in it to take it.
  • 32:28To believe that it was safe
  • 32:31and that it was critical,
  • 32:33particularly for our population which was
  • 32:36being impacted in such a dramatic way. Um?
  • 32:42I could talk all day. Dean, is that
  • 32:45the only question you have for me?
  • 32:48Well, tell us a little bit about the impact
  • 32:51that Covid has had on your community.
  • 32:56I think I think Colbert has
  • 32:58has impacted all of our
  • 33:00communities, but I think for minorities it's
  • 33:02it's hit us three or four times as hard.
  • 33:06So within with regards to unemployment with
  • 33:10regards to housing with regards to stress,
  • 33:14I mean just being on lockdown not
  • 33:19being accessible to mass or two.
  • 33:23Even to have a primary care physician,
  • 33:26I mean, it's it's a it's very difficult
  • 33:28and So what we've been trying to do
  • 33:31in for our seniors in particular.
  • 33:33Who may not be able to do Tele medicine
  • 33:36or to get on Azum call because they don't
  • 33:39have Wi-Fi or they don't have a computer
  • 33:42and they're still using flip phones, so.
  • 33:45What we've been trying to do is
  • 33:47cultural ambassadors is to somehow
  • 33:49mediate between these in equities,
  • 33:52so it's saying Stevens,
  • 33:53one of the things we did.
  • 33:55We had a class that yell helped us
  • 33:58sponsored a pilot program where we work
  • 34:01with twelve seniors to show them how they
  • 34:04could get on and and do Tele medicine,
  • 34:07how they could find their doctor,
  • 34:09how they could get an email,
  • 34:11an access to zoom.
  • 34:14Phenomenal.
  • 34:15It was empowering to see them to do that.
  • 34:21So that was one of the things
  • 34:23that that that we were able to do.
  • 34:26Many of our churches and many in our
  • 34:28community are doing things like food banks
  • 34:31and they're trying to help with jobs,
  • 34:33and this is one of the things we also
  • 34:35do in one of the places that I work.
  • 34:38You know,
  • 34:39like there's a platform to employment,
  • 34:41we have to work with ex offenders who
  • 34:43are dads who don't get to see their
  • 34:45children who have no jobs and no
  • 34:47possibility of jobs because of their record.
  • 34:50I mean, it's just.
  • 34:51It's just.
  • 34:52It's devastating and.
  • 34:56If there was any anytime in America when
  • 34:59America needs to come together and start
  • 35:01at the bottom up, this is that time.
  • 35:03And I want you know,
  • 35:05I just I love the fact I tell all
  • 35:08my friends and all my congregants.
  • 35:10I got the shot.
  • 35:12That's that's that's good news.
  • 35:14That's gospel news.
  • 35:16I got.
  • 35:16The shot is as Marsella said to me once,
  • 35:20is either the the vaccine or it's the virus.
  • 35:24So that's that's that's the good news here.
  • 35:28Thank you, Reverend Clayton.
  • 35:30Do you want to add anything too?
  • 35:34It's hard to follow
  • 35:35Reverend Perry, I know, but.
  • 35:39Thank you Dave Brown. Yes it is.
  • 35:43Doctor Perry covers the whole ballpark, but.
  • 35:49The kalvik impact that that I have seen.
  • 35:53And experience first of all covert
  • 35:56had impacted every area. About lives.
  • 36:00I don't know of anything else that
  • 36:02has shipped down the entire world.
  • 36:05Our schools had closed.
  • 36:07the University had closed for period of time.
  • 36:10Hospitals and convalescent
  • 36:12homes had to end visitations.
  • 36:15Um, I had half a 7 year old
  • 36:19granddaughter who lived in Denver and.
  • 36:22I asked her last November I said
  • 36:23what do you want? Granddaddy too?
  • 36:26Get you for Christmas.
  • 36:28She said Granddaddy,
  • 36:29I want you to go to your computer.
  • 36:33And buy airline ticket for you and Grandma.
  • 36:36And come and visit us.
  • 36:40But we can't.
  • 36:41We couldn't do that because of the pandemic.
  • 36:45Think about it, banks and financial
  • 36:48institutions have to cut back.
  • 36:50And I don't know if anything
  • 36:52else that have shut down churches
  • 36:54in the House of worship and it.
  • 36:57It's a.
  • 36:57It's a difficult thing when
  • 36:59you can't gather for worship.
  • 37:01To worship a God and in times of death
  • 37:05and and we passed his no longer can
  • 37:08hold the hands of parishioners and
  • 37:11loved ones and comfort family so so.
  • 37:14This was a difficult period
  • 37:16for so many people.
  • 37:19Kovik have impacted me and millions
  • 37:21of others in every area of life,
  • 37:24but I I think God that there is a bright
  • 37:28light shining at the end of the tunnel.
  • 37:31I thank God that the vaccines are available.
  • 37:35I thank God that things are getting better.
  • 37:39I think God for days like this when we
  • 37:42have such a great panel who can give
  • 37:46accurate knowledge to to help so many people.
  • 37:50And encourage us with news about the
  • 37:53pandemic and that this will pass pretty soon.
  • 37:56We hope we are rising.
  • 37:59We've got we're gonna get through
  • 38:02it if we keep.
  • 38:04Study and continue to wash our
  • 38:06hands and and social distance.
  • 38:09Even though we,
  • 38:11I've already received my shots, we got ours.
  • 38:16Doctor Perry back in August.
  • 38:19And and what a blessing that was.
  • 38:22So I think I'll stop there.
  • 38:26Thank you.
  • 38:29Doctor ball sack
  • 38:33I think. It is the CMO of a
  • 38:36hospital where many physicians have
  • 38:38held the hands of patients, and.
  • 38:41When family haven't been present,
  • 38:43we've seen a lot, but today
  • 38:45I'm going to ask you about.
  • 38:49Vaccination and ask you to speak a
  • 38:52little bit about what the health system.
  • 38:55Is doing to address Covid still today and
  • 38:57a little bit about the vaccine delivery
  • 39:00efforts of the young human health system?
  • 39:02Sir, thank you. Doctor Brown.
  • 39:04It's as you said, Reverend Clayton.
  • 39:06It's a little tough to follow
  • 39:08this incredible group.
  • 39:09I don't want to go back over the
  • 39:12same territory, but I want to
  • 39:15pick up where Doctor Nunez Smith.
  • 39:17Noted two things.
  • 39:19One is the incredible devastation
  • 39:21and death and and terrible
  • 39:23things that have happened.
  • 39:24And you know,
  • 39:25I think we need to acknowledge
  • 39:28that in our own health system
  • 39:30there have been over 1000 deaths,
  • 39:33and while we've treated.
  • 39:34More than 6000 individuals and
  • 39:36discharged majority of them Home,
  • 39:385000 of them home.
  • 39:40We've had 5000 deaths and it's
  • 39:41important to note that every single
  • 39:43one of those is so important,
  • 39:45but I want to pivot quickly
  • 39:47to what you just talked about.
  • 39:49Which is, you know,
  • 39:50some of the amazing things
  • 39:52that we've experienced,
  • 39:53and I think the vaccine is only the
  • 39:56latest one of the things that I feel
  • 39:58that's happened, at least in our.
  • 40:00Our communities is we've come together.
  • 40:02I think in a way that we haven't seen
  • 40:04in the past and I really appreciate
  • 40:07being part of this panel and I
  • 40:09really appreciate the opportunity
  • 40:11to highlight some of the things
  • 40:13like Teacher was talking about,
  • 40:14which was the cultural ambassadors.
  • 40:16I mean,
  • 40:17we are blessed to be in the
  • 40:19community that we are in to have
  • 40:21the resources that we have,
  • 40:23including the YCC.
  • 40:24I to have you all as cultural
  • 40:26ambassadors to do things like help
  • 40:28bring the Pfizer vaccine trial to New
  • 40:30Haven and improve our ability to do trials.
  • 40:33And I think we've come together in
  • 40:36terms of how we've cared for patients.
  • 40:39You know we've cared for these 4000
  • 40:41patients because all walks of physicians,
  • 40:44nurses, pharmacists,
  • 40:44respiratory therapists,
  • 40:45dropped whatever they were doing,
  • 40:47and they ran to the fire to help.
  • 40:50An we met that challenge and then
  • 40:53when we had to stand up testing
  • 40:55and you know one of the great
  • 40:57benefits we have is the Yale School
  • 40:59of Medicine and the Incredible
  • 41:01Talent of the Yale Physicians.
  • 41:02One of those yellow physicians created
  • 41:04the first non commercial covid test
  • 41:06in the country that was FDA approved.
  • 41:08Doctor Marie Landry did.
  • 41:09And then we stood up testing sites in
  • 41:12all of our cities and in our communities.
  • 41:14And again we met that challenge.
  • 41:16All of our staff.
  • 41:18Random that.
  • 41:19And now we're doing the same
  • 41:21thing with vaccination.
  • 41:21We're blessed as Doctor Denise Smith said.
  • 41:24Now with three great vaccines that
  • 41:25I can't believe that you know,
  • 41:27you can read the articles
  • 41:29about how they were done.
  • 41:30There's a great expozay in the
  • 41:32Washington Post about the scientists
  • 41:33that develop them and how they did it.
  • 41:36And it's just brilliant science.
  • 41:37And now we have the ability to deliver them.
  • 41:40And so far since December 15th.
  • 41:42We vaccinated more than 100 and
  • 41:4515,000 individual shots and in that
  • 41:47we vaccinated about 70,000 people.
  • 41:50With both doses,
  • 41:51we still have about another 30,000 to
  • 41:54get the second dose and hopefully many,
  • 41:57many more 100,000. With regard to what you,
  • 42:00what Doctor New Smith addressed around the
  • 42:03two things that I think we've all identified
  • 42:05as challenges to getting our broad black and
  • 42:08Brown citizens and colleagues vaccinated.
  • 42:10Really, the two things that she
  • 42:12highlighted we've been trying really hard.
  • 42:14Not just at our health system,
  • 42:16but really with our friends and
  • 42:18partners across the state to address.
  • 42:201 is the access issue we've placed
  • 42:22our vaccine sites in our communities.
  • 42:24So in New Haven at Floyd Little in Bridgeport
  • 42:27at the University of Bridgeport at the.
  • 42:30Wheeler Center in New London at
  • 42:32Mitchell College and she also mentioned
  • 42:34how we might be able to mobile sites
  • 42:37while we're doing pop up sites.
  • 42:40Yesterday we did one at the Bethel a
  • 42:42Me Church and it was a success and
  • 42:45tomorrow will be at the Christian
  • 42:47Tabernacle Baptist Church as well.
  • 42:50These are not mass vaccination sites at
  • 42:52the large sites like Floyd Little we can
  • 42:55deliver 1000 vaccines a day but still access.
  • 42:58There is a challenge because.
  • 43:01As folks have said,
  • 43:01you have to you have to navigate an
  • 43:04appointment and getting the first
  • 43:05appointment is tough once you're there.
  • 43:07Once you're in,
  • 43:08we help you with getting the 2nd
  • 43:10appointment so you don't leave the
  • 43:12site if you until you have that
  • 43:14second appointment scheduled.
  • 43:15So how are we doing that?
  • 43:17How are we working on access there?
  • 43:19Well,
  • 43:19we've partnered with the State of
  • 43:21Connecticut State of Connecticut
  • 43:22has a 211 information call.
  • 43:24If you call 211,
  • 43:25they will help navigate you
  • 43:26to the closest place,
  • 43:28whether it be one of our sites.
  • 43:30One of the local health Department's
  • 43:32one of the other hospitals.
  • 43:33Or health systems,
  • 43:35but you can also call R 833.
  • 43:39Ask YNHH and they'll help you.
  • 43:43We've also piloted very successfully
  • 43:45reverse 911 so many of us have
  • 43:49registered and four in our towns that
  • 43:51if there's a disaster that they send
  • 43:54us a text message to our phones.
  • 43:57We use that information.
  • 43:58We've partnered with the State of
  • 44:01Connecticut and we're targeting zip
  • 44:03codes where we're seeing particularly
  • 44:05those zip codes that Doctor Nunez Smith
  • 44:08mentioned that have a very bad SVI.
  • 44:10And we've partnering calling those
  • 44:12individuals and then preferentially
  • 44:14allowing them.
  • 44:15To get to the head of the line.
  • 44:18But still we're not making the
  • 44:20progress that we'd like to see,
  • 44:21so we're going to have to be smarter.
  • 44:24We're going to have to listen
  • 44:26to our communities about how we
  • 44:28can get registration better,
  • 44:29and I think I think information and
  • 44:31discussions like this can help.
  • 44:33So we stand, you know,
  • 44:34very ready to continue vaccinating.
  • 44:36And by the way, it's not just us.
  • 44:39We have community partnerships
  • 44:40with our city and state and
  • 44:41Community health Department's,
  • 44:43and we're working very effectively with them.
  • 44:45And our federally qualified health centers.
  • 44:48And every week we sit, we strategize.
  • 44:50We share resources.
  • 44:52We share vaccine.
  • 44:53We're trying to get everyone
  • 44:55vaccinated as fast as we can.
  • 44:58So thank you for letting us be part of this.
  • 45:01And you know, again,
  • 45:02one of the things that I feel is I
  • 45:05feel a sense of connected community
  • 45:06that I think is enhanced through this
  • 45:09one bright thing that I think we've
  • 45:11seen the other is is that we have met
  • 45:13all of these challenges and every
  • 45:15time we meet one of these challenges,
  • 45:18it's impressive to me how
  • 45:19we rise to overcome it.
  • 45:21And I'm sure we're going to do this more.
  • 45:24Thank
  • 45:24you. Thank you, Tom.
  • 45:27Doctor sholl the sum of what Tom
  • 45:31mentioned involved. For example,
  • 45:34reverse 911 involves using informatics
  • 45:37in our electronic health record.
  • 45:40Both to reach patients and also I think
  • 45:43to to modify some of our treatment
  • 45:45protocols in the early days of covid.
  • 45:47As we were learning more about the virus,
  • 45:50can you share a little bit about the
  • 45:53electronic health record and the role
  • 45:55it's played both in the treatment of
  • 45:57Covid and now in vaccination there? Thank
  • 45:59you, Dean Brown and thank you to
  • 46:01the Culture ambassadors in the
  • 46:03community is up his information,
  • 46:05but I think to your point, Dean Brown,
  • 46:07the electronic health records,
  • 46:09been incredibly powerful for us as a tool to
  • 46:12help fight covid even from the beginning.
  • 46:14As we started realizing that Covid
  • 46:16was taking hold of Connecticut,
  • 46:18we use it to track the number of
  • 46:20positive test results there coming
  • 46:22across state and were able to the Geo
  • 46:24map and see where the hotspots were.
  • 46:26We were able to then start building
  • 46:29dashboards to track our admissions to
  • 46:31the different hospitals and it trickled
  • 46:33in the beginning and then became a big
  • 46:35wave as I think many people know where we,
  • 46:38you know had hundreds of patients
  • 46:39at all of our different hospitals
  • 46:41and with the dashboards and the.
  • 46:43Information from the electronic
  • 46:45health record system.
  • 46:46We could track how many patients we
  • 46:48had in each of the different hospitals,
  • 46:51how many ICU, how many were on ventilators,
  • 46:55who was doing well, who wasn't,
  • 46:57and be able to deploy resources.
  • 46:59Scarce PPE, you know,
  • 47:01personnel to different hospitals,
  • 47:02even transfer the sickest patients
  • 47:04you know to others and to your point.
  • 47:07It was also very critical for our
  • 47:10treatment strategy and we had
  • 47:13a team of experts.
  • 47:14That were working night and
  • 47:16day to ask hour for,
  • 47:17you know for all the latest
  • 47:19evidence that was coming across an
  • 47:21experience from other institutions
  • 47:22in the in the literature and we're
  • 47:25constantly refining the protocols,
  • 47:27treatment protocols that we would
  • 47:28recommend as our standard of care.
  • 47:30And then we would use electronic
  • 47:33health record to roll that out.
  • 47:35So no matter which of our seven
  • 47:37hospital campuses patients were at,
  • 47:39they were getting the latest
  • 47:40greatest advice and evidence
  • 47:42based medicine guidelines that are
  • 47:44experts for identifying so.
  • 47:45Extremely powerful and and you know
  • 47:47with with the vaccination to your point,
  • 47:50it's also been extremely powerful.
  • 47:52Tool is Doctor Ballsack mentioned.
  • 47:53You know the different strategies
  • 47:55with reverse 911 and folks can you
  • 47:58know can call our different hotlines.
  • 48:00Folks can also make appointments
  • 48:01using our patient portal.
  • 48:03My chart as another option and we
  • 48:05want to make it as easy as possible
  • 48:07and all the different methods are all
  • 48:10important avenues to get vaccination.
  • 48:12And so whether you have my chart
  • 48:15account or not,
  • 48:16we've set up websites where people can.
  • 48:18Log in to answer the screening questions
  • 48:20and then as soon as vaccinations available,
  • 48:23they can sign up for those vaccinations
  • 48:25and then we use the system to track
  • 48:28when they need a second dose.
  • 48:30If it's one of those vaccines that
  • 48:32need two doses and help them schedule
  • 48:35easily so they can leave their first
  • 48:37dose appointment with an appointment
  • 48:39for the 2nd one so the electronic
  • 48:42health record system has been extremely
  • 48:44integral to both vaccination and
  • 48:45to our initial battle.
  • 48:47Andcontinued battle with Covid.
  • 48:51Thank you we have a number of
  • 48:54questions that have been submitted.
  • 48:56I think Admiral Rojo I'm going
  • 48:59to direct this one to you.
  • 49:01The question is that.
  • 49:03After the FDA approved the vaccines,
  • 49:06the need to administer a series of two
  • 49:09doses was was determined and now the
  • 49:12latest vaccine requires a single dose.
  • 49:15Can you explain a little bit about the
  • 49:18process through which it was determined?
  • 49:21How many doses of vaccine might be needed?
  • 49:28Sure, I am happy to kind of start
  • 49:30and provide some information,
  • 49:32and if they you know a process where,
  • 49:35for example, we actually have a range
  • 49:37of resources on our FDA website which
  • 49:39I think is really important to know
  • 49:41because it actually goes through the
  • 49:43entire vaccine approval process,
  • 49:45which is really helpful to understand
  • 49:47because then you can also understand,
  • 49:49as we heard earlier, how,
  • 49:51of course the vaccines right
  • 49:52now have been authorized under
  • 49:53emergency use authorization,
  • 49:55so it talks about that process
  • 49:57and it also talks about.
  • 49:59The process for vaccine approval.
  • 50:01For all of the vaccines and we talked about
  • 50:03the three vaccines that are out there,
  • 50:06we've talked about,
  • 50:07there's also been advisory committee
  • 50:09meetings that have been really important.
  • 50:11Those Advisory Committee meeting certain
  • 50:12discussion related to that entire process,
  • 50:14and we've been able to also get public
  • 50:17feedback and the basically as far as
  • 50:19the approval is based off the data
  • 50:21that is submitted an our career.
  • 50:23Scientists at FDA review that data
  • 50:25is very rigorous process.
  • 50:26They review that data and based off the data.
  • 50:29Also, of course we have the Public
  • 50:32Advisory Committee meeting.
  • 50:33That's how those decisions are made,
  • 50:34and the other thing that I will highlight
  • 50:37again that I think is really important.
  • 50:39It's important to understand that
  • 50:40process and we have an entire vaccine
  • 50:42101 web page on the FDA website that I
  • 50:45think is really important and helpful.
  • 50:46There is even an infographic that
  • 50:48kind of walks you through what
  • 50:50that process looks like.
  • 50:52Great, will try to get that
  • 50:54up on the chat if we can. Uh.
  • 50:57Honey, I wonder if you could expand
  • 50:59a little bit on this and from based
  • 51:03on data from trials and related
  • 51:05question that people have is.
  • 51:08For those who have been vaccinated,
  • 51:09what do we know about how long it lasts,
  • 51:12and whether there will be a need for a
  • 51:14booster at those sorts of questions? Yeah,
  • 51:17that's a great question that we
  • 51:19don't have all the answers to,
  • 51:21so we know that the clinical trials
  • 51:24have really been going on in the
  • 51:26most part for less than a year,
  • 51:28especially for the phase three trials.
  • 51:30But with their starting to be emerging
  • 51:32data from the earlier phase trials,
  • 51:34for example, there will be there in
  • 51:36a group have published every 120
  • 51:38days after the first fascination.
  • 51:40Still showing robust trajectory's of both
  • 51:42antibodies and and neutralizing titers.
  • 51:44The little bit of a droplet still
  • 51:46sufficient to be able to work.
  • 51:48Protect against infection.
  • 51:49We think now the problem is that we
  • 51:52don't have great information about
  • 51:53what the correlates of immunity are.
  • 51:55So for example,
  • 51:56what antibody levels you know
  • 51:58afford protection?
  • 51:58So there's still a lot more
  • 52:00to be learned about that,
  • 52:01but the clinical trials are going on
  • 52:04for awhile and the phase three trials
  • 52:06will be going on for three years,
  • 52:08and there's going to be longitudinal
  • 52:10assessments of the antibody levels overtime,
  • 52:12and I think we're going to learn
  • 52:14so much more,
  • 52:15but I think based at least on the
  • 52:17early data on this trajectory is,
  • 52:19you know.
  • 52:19And in the absence of any
  • 52:21variants that seriously evade the
  • 52:23current vaccine responses,
  • 52:25you know that we think that at least
  • 52:27you know for the next year or so,
  • 52:30people who are vaccinated should
  • 52:31be protected, but that can change.
  • 52:36Thank you Reverend Perry and Clayton,
  • 52:38both of you volunteered for vaccine
  • 52:42trials in August at a time when we
  • 52:45did not know a lot about them and
  • 52:49when you also had the possibility
  • 52:52that you might receive a placebo
  • 52:55rather than the active vaccine.
  • 52:58Um? Tell us a little bit about why
  • 53:02you participated, were you afraid?
  • 53:06Would you recommend that others
  • 53:07participate in clinical research?
  • 53:13Hi Dean Brown, there was No
  • 53:16Fear because we knew that
  • 53:19by the time it got to face,
  • 53:22three is relatively safe.
  • 53:25Um? I was hoping that I.
  • 53:29Received the actual vaccine,
  • 53:31and because I didn't have
  • 53:33any affect from the shots,
  • 53:36I thought I probably got the placebo.
  • 53:39But when the study became an unblinded,
  • 53:42I realized that it got the actual
  • 53:46VAC vaccine and boy was a happy day.
  • 53:51So so. And I I did this because, you know.
  • 53:58Early on there were few people of color
  • 54:02that participated in the study. I think.
  • 54:07Before we got before we completed it,
  • 54:10I think we were up to about 41% so.
  • 54:15I think we did a little help too to help
  • 54:19our cause and because of it I think.
  • 54:22Our community and the world have been helped.
  • 54:28Reverend Perry yes I.
  • 54:31I agree with my colleague. I
  • 54:35think one of one of the things that
  • 54:37a person had when we've been trying
  • 54:40to suggest our community is that we
  • 54:43need to take charge of our health.
  • 54:45And you know, we just can't
  • 54:47depend on other people.
  • 54:48We really have to stand up man up,
  • 54:51woman up and take charge of our health.
  • 54:53I was mentoring a young fellow,
  • 54:55one of one of the dads in my program
  • 54:58and as a cultural ambassador.
  • 55:00I was telling him about the Pfizer
  • 55:02study and I was saying man,
  • 55:04you can you can you can go down to
  • 55:06yell and maybe get the vaccine or
  • 55:09if not the placebo but you would be
  • 55:12in the study and you'd be helping
  • 55:14yourself and so many other people.
  • 55:16And he said to me, not, don't do it.
  • 55:20He said, wait?
  • 55:21And that's that's that's part
  • 55:23of our community.
  • 55:25Wait and see how other people.
  • 55:27React and what happens to them?
  • 55:30And so I said to him.
  • 55:32But if if we wait,
  • 55:34we may not be around to see the results
  • 55:38of how this affects other people,
  • 55:40because we won't be here.
  • 55:43And then I realized that maybe
  • 55:45what I needed to do was to
  • 55:47demonstrate when I was putting you.
  • 55:48Like you said,
  • 55:49put your money where your mouth is.
  • 55:51I said maybe I need to just.
  • 55:54My example lead,
  • 55:55and I think that that was one
  • 55:59of the motivating events that
  • 56:01led me to go ahead and.
  • 56:04And sign up for the study and then.
  • 56:07I asked my daughter. Who is 28 and.
  • 56:13You know, young people.
  • 56:14I'm always impressed with them.
  • 56:16I I I just don't understand them so.
  • 56:20I was expecting her to say no
  • 56:22and then she said yes and I said,
  • 56:24wow,
  • 56:25that's really interesting because
  • 56:26the people that I were talking to
  • 56:29basically were in her age group were really.
  • 56:31They did not believe that it was important.
  • 56:33The other thing you know when we look
  • 56:36at social determinants of health.
  • 56:37But we don't sometimes look at his is
  • 56:40the mindset of people who are at the bottom.
  • 56:43Who have a sense of hopelessness.
  • 56:45And so when it comes to death,
  • 56:48it's almost like.
  • 56:50It's not a great importance to them.
  • 56:52It's like living Diridon died kind of thing,
  • 56:54so it's kind of, you know you gotta
  • 56:56reach out to these people and say,
  • 56:58but you're important.
  • 56:59You want to be around for your children?
  • 57:01You wanna be around for your parents.
  • 57:02You want to be around, you know.
  • 57:04Because you can be around if
  • 57:06you take charge of your health,
  • 57:08but if you don't.
  • 57:10Then there are consequences that
  • 57:12not only gonna affect you,
  • 57:14but your community.
  • 57:15So I heard when Doctor Talk about her
  • 57:19community and another doctor said no,
  • 57:21it's not hurt its community.
  • 57:23But we weren't what we're interested
  • 57:26in is safeguarding our community,
  • 57:28empowering our community,
  • 57:29vaccinating our community.
  • 57:30And when we do that.
  • 57:33The outrage and the platform is.
  • 57:36Becomes enormously large and meaningful,
  • 57:39and that's what we have to do.
  • 57:45Thank you.
  • 57:48Oh, there are a couple of
  • 57:50questions that have come in
  • 57:53while we've been speaking and.
  • 57:55One question and I'm not sure,
  • 57:57maybe Tom the question is.
  • 58:01This may be also marcella,
  • 58:04if if we could speak to the challenges
  • 58:07of vaccinating undocumented,
  • 58:09an refugee populations in what
  • 58:12programs might be in place. Sure
  • 58:16we have. You know we have a program
  • 58:19that we didn't start it out this way,
  • 58:22but it is turned out to be a way for
  • 58:25undocumented individuals to get healthcare.
  • 58:28And it's our program called Project Access.
  • 58:30It's on York Street.
  • 58:32It's right underneath the Air
  • 58:34Rights garage and it was set up.
  • 58:37Initially modeled after other programs
  • 58:39around the country to give access
  • 58:41to individuals who may not have
  • 58:43it because of lack of insurance.
  • 58:45Access to specialty care.
  • 58:48And now every year we navigate
  • 58:50hundreds and hundreds of folks.
  • 58:52Right now it's primarily undocumented
  • 58:54because of the Affordable Care Act.
  • 58:56Many of the folks that didn't have
  • 58:58insurance had access now to Medicaid
  • 59:01and other types of insurance products,
  • 59:03so we've been using our known list
  • 59:05of individuals who are undocumented
  • 59:07because they've received care
  • 59:08through project access and we try
  • 59:11to keep those lists separate,
  • 59:12and I can describe that later if you'd like,
  • 59:16and we're trying to reach out to them.
  • 59:19But we you know the vaccine is
  • 59:22free if you have no insurance,
  • 59:25you don't need to pay anything for it all.
  • 59:29You'd simply need to do is give us your name.
  • 59:33If you register you and of course
  • 59:36your immigration status is not
  • 59:39at all anything that we ask for.
  • 59:41Look for have any interest in verifying
  • 59:44so you know those populations can be hard,
  • 59:48very hard to reach.
  • 59:50And again,
  • 59:51we're trying through a couple
  • 59:52of different levers to do that,
  • 59:53but let me ask Marcel if she has other ideas,
  • 59:56and maybe there's some folks here
  • 59:57on the phone who might also give
  • 59:59us some additional ideas.
  • 01:00:00Anecdote perfect so.
  • 01:00:04So glad to have you talk about
  • 01:00:06project access such a great
  • 01:00:08asset in our in our community.
  • 01:00:09You know, I would say that kind
  • 01:00:11of part of that question too,
  • 01:00:13or some of the concerns that
  • 01:00:15might be unique to people who are
  • 01:00:17undocumented or refugees and so
  • 01:00:19really important to speak to it.
  • 01:00:20I would just pick up where you left
  • 01:00:22off one of the key principles here
  • 01:00:24of course is making sure that people
  • 01:00:27don't have any surprise costs or no
  • 01:00:29out of pocket cost for the vaccine.
  • 01:00:31You know, one of the things that we're doing.
  • 01:00:34And the federal ministration, too,
  • 01:00:36is is trying to communicate and
  • 01:00:38grateful for this opportunity.
  • 01:00:39Some of those other things that
  • 01:00:41come up as well.
  • 01:00:43For example,
  • 01:00:43you know what is the flow of data, right?
  • 01:00:46As people are registering
  • 01:00:48and giving information,
  • 01:00:49there often are concerned about kind of.
  • 01:00:51Where will data go and so important to stay
  • 01:00:54here tonight that there are firewalls, right?
  • 01:00:57None of the data collected in terms of
  • 01:00:59registration for vaccination goes to,
  • 01:01:01for example,
  • 01:01:02immigration or Immigration Services.
  • 01:01:03We have made it very clear.
  • 01:01:05That all vaccination sites are
  • 01:01:07immigration enforcement free zones,
  • 01:01:09right?
  • 01:01:09So there will be no immigration activity
  • 01:01:12at any vaccination site that is critical.
  • 01:01:14You know other things too early on.
  • 01:01:17You know the registration systems.
  • 01:01:19Many of them were asking people
  • 01:01:22questions such as are you a US
  • 01:01:24citizen at time of registration
  • 01:01:25you know we have to get rid of
  • 01:01:28those barriers as well as asking.
  • 01:01:32But people about,
  • 01:01:33in addition to the immigration status
  • 01:01:35asking for kind of mandated identification,
  • 01:01:37so these are some of the specific
  • 01:01:39structural barriers as we've been talking
  • 01:01:41about tonight that have to be overcome.
  • 01:01:44You know,
  • 01:01:44I think so many people have said it tonight.
  • 01:01:47One of the things that's
  • 01:01:49incredibly valuable is listening,
  • 01:01:50engaging with communities.
  • 01:01:51Communities are experts in what they need.
  • 01:01:54Most we've been able to have great
  • 01:01:56stakeholder conversations with
  • 01:01:57advocates representing these very
  • 01:01:58communities who made clear like
  • 01:02:00these are what the barriers are.
  • 01:02:02These are some of the concerns
  • 01:02:04that are unique.
  • 01:02:05Back to the trusted messengers again.
  • 01:02:07So it's making sure the policies are
  • 01:02:09in place to promote vaccination,
  • 01:02:11but also the trusted messengers.
  • 01:02:13Know that and can share that
  • 01:02:15information with those communities who,
  • 01:02:16for lots of understandable reasons
  • 01:02:18might might have hesitancy about
  • 01:02:19getting vaccinated.
  • 01:02:20And I think that's an important,
  • 01:02:22maybe said for other parts of
  • 01:02:24the conversation,
  • 01:02:24we talk about vaccine confidence.
  • 01:02:26You know the questions people have about
  • 01:02:29vaccination are going to be really unique,
  • 01:02:31and so we have to keep in mind that
  • 01:02:33these messages have to be tailored.
  • 01:02:35One person might be thinking about.
  • 01:02:37Immigration enforcement and somebody
  • 01:02:38else might be thinking about infertility.
  • 01:02:40So how do we make sure that we are
  • 01:02:42addressing all of these different
  • 01:02:43concerns and that people are
  • 01:02:45hearing this from the folks that
  • 01:02:46they trust to hear that
  • 01:02:47information from?
  • 01:02:50Make it related to that.
  • 01:02:52Only one of the questions in the
  • 01:02:54chat relates to vaccine rates among
  • 01:02:56our military and this sort of urban
  • 01:02:59legend that circulates about side
  • 01:03:02effects of vaccines. How do you?
  • 01:03:06How do you talk with patients about
  • 01:03:09those things and educate about side
  • 01:03:11effects or lack of side effects? Yeah,
  • 01:03:14so part of my messages messages that
  • 01:03:16side effects happen and they happen
  • 01:03:19with every vaccine under the sun,
  • 01:03:21and so they're reasonably to be expected.
  • 01:03:23The other message I have is that you
  • 01:03:25know the side effects that happen with
  • 01:03:28the vaccines are in majority of cases
  • 01:03:30a good thing because they correlate
  • 01:03:32pretty well with developing appropriate
  • 01:03:34immune responses to the vaccine.
  • 01:03:36Two reasons why I say that one is
  • 01:03:38we find that younger individuals
  • 01:03:39tend to have more of those side
  • 01:03:42effects than older individuals,
  • 01:03:44and we know that's because younger
  • 01:03:46people tend to have much more robust.
  • 01:03:49Antibody responses to the vaccine.
  • 01:03:50Another observation which buttress is that
  • 01:03:53point is that people also tend to have
  • 01:03:56more side effects with the second dose,
  • 01:03:58and looking at some of the early phase
  • 01:04:01immunogenicity data or the data around
  • 01:04:03what happens to the antibody levels with
  • 01:04:06the second dose should support the second.
  • 01:04:08Those and there corresponds
  • 01:04:10very well with that.
  • 01:04:11So in general I tell people receiving
  • 01:04:14the vaccine to expect some some some
  • 01:04:16occur more frequently than others.
  • 01:04:18But they're really just a good sign that
  • 01:04:21your body is responding well to the vaccines.
  • 01:04:24And again,
  • 01:04:24I remind everyone that you know
  • 01:04:26severe adverse events that lead to
  • 01:04:28hospitalization and death were literally
  • 01:04:30unheard of in the vaccine platforms that
  • 01:04:33I received emergency use authorization.
  • 01:04:34So these vaccines really have
  • 01:04:36a great safety record,
  • 01:04:37and you know the side effects when they
  • 01:04:40do occur tend to be mild to moderate.
  • 01:04:43They happen at Year 2 after vaccination.
  • 01:04:45They resolved pretty quickly,
  • 01:04:46and frankly, there well worth it.
  • 01:04:48Comparing to the protection that
  • 01:04:50you get from from the
  • 01:04:52vaccine. Thank you.
  • 01:04:56Admiral Rojo, one of the.
  • 01:05:00Characteristics of the vaccine
  • 01:05:02trials is that there were
  • 01:05:04many minority participants,
  • 01:05:06and your office has been
  • 01:05:08very engaged in increasing,
  • 01:05:11as you mentioned at the outset,
  • 01:05:14the participation of those who were
  • 01:05:17underrepresented in in trials.
  • 01:05:19Can you talk?
  • 01:05:20A little bit more about the importance
  • 01:05:22of that and its impact on our
  • 01:05:25treatments that we have to offer.
  • 01:05:29Sure, absolutely, and I also want to kind of
  • 01:05:31circle back really quickly just to comment
  • 01:05:33on something that was just mentioned,
  • 01:05:35'cause I think it's in really important
  • 01:05:37to know the types of information and
  • 01:05:39resources that are available to all of us.
  • 01:05:41We've been talking, of course,
  • 01:05:43about vaccines we understand.
  • 01:05:44Of course, when we talked about vaccine
  • 01:05:46hesitancy and one of the things that
  • 01:05:48I think is really important to know.
  • 01:05:50For example, are FDA Center for
  • 01:05:52biologics evaluation and research.
  • 01:05:53They are responsible for the
  • 01:05:54oversight of vaccines at FDA,
  • 01:05:56our agency, being a Regulatory agency.
  • 01:05:58We have, of course,
  • 01:05:59rigorous standards for safety.
  • 01:06:00Accuracy and effectiveness and
  • 01:06:01one of the things that I think
  • 01:06:04as we've all talked about,
  • 01:06:05we know that vaccines are one of the safest
  • 01:06:07ways to help prevent infectious diseases.
  • 01:06:10Like COVID-19 they can protect you
  • 01:06:11and your loved ones, so it's so
  • 01:06:13important for us to get vaccinated.
  • 01:06:15It's also important for you to
  • 01:06:17know where you can get resources,
  • 01:06:19and I did want to highlight that for FDA
  • 01:06:21we have our COVID-19 vaccines web page.
  • 01:06:24It has information related to
  • 01:06:25emergency use authorization,
  • 01:06:26EUA.
  • 01:06:27All the terminology that you're
  • 01:06:28hearing us talk about tonight
  • 01:06:30when we talk about vaccines.
  • 01:06:31And it has a lot of information
  • 01:06:33there that I think is really helpful.
  • 01:06:35So I did want to add to the conversation
  • 01:06:37about the resources because I think
  • 01:06:39it's really important for all of us
  • 01:06:41and something that we've been really
  • 01:06:43focused on throughout this pandemic
  • 01:06:44to make sure all of us are diverse
  • 01:06:46communities that public overall that we
  • 01:06:48have current and accurate information
  • 01:06:49so that we can all make informed decision.
  • 01:06:52So I wanted to make sure that I highlighted
  • 01:06:54that resource diversity in clinical trials.
  • 01:06:56That's a key priority for our office.
  • 01:06:58Is something that we've been
  • 01:06:59working on for a very long time,
  • 01:07:01so I know of course with
  • 01:07:03COVID-19 with the pandemic.
  • 01:07:04It has really raised awareness
  • 01:07:06about the issues that we've been
  • 01:07:07working to address for many,
  • 01:07:09many years in the in equities that our
  • 01:07:12communities have faced and one of those,
  • 01:07:14of course is our work to advance
  • 01:07:15racial and ethnic minority
  • 01:07:17participation in clinical trials.
  • 01:07:18We have long work to do this.
  • 01:07:21At FDA we have hosted public meetings.
  • 01:07:23We've developed tools.
  • 01:07:24We've also issued guidance documents,
  • 01:07:25which is a way for us to
  • 01:07:27communicate to the public.
  • 01:07:29Our current thinking.
  • 01:07:30Of course,
  • 01:07:30that they mention diversity in
  • 01:07:32clinical trials is a priority.
  • 01:07:34In support of our agency efforts,
  • 01:07:36our office developed a ongoing
  • 01:07:38public education and outreach
  • 01:07:39campaign and that campaign really
  • 01:07:41works to try to overcome some of the
  • 01:07:44barriers from diverse communities.
  • 01:07:45From participating in clinical trials,
  • 01:07:47making sure that we have resources
  • 01:07:49available that highlight,
  • 01:07:50for example, what a clinical trial is,
  • 01:07:52what it means to participate
  • 01:07:54in the clinical trial,
  • 01:07:56and why we need diverse participation.
  • 01:07:58We have videos we have public
  • 01:08:00service announcements we engage
  • 01:08:01in social media outreach.
  • 01:08:03We really work at amplify these messages,
  • 01:08:05especially during.
  • 01:08:06COVID-19 because it was so important
  • 01:08:08for us to have diverse representation
  • 01:08:10not only in our vaccine trials,
  • 01:08:12but also in the treatment
  • 01:08:13trials that were ongoing.
  • 01:08:14So we really work to amplify those
  • 01:08:16messages about the importance of
  • 01:08:18diverse participation and also
  • 01:08:19as part of this ongoing campaign.
  • 01:08:21Again work that we've been
  • 01:08:23doing for a number of years.
  • 01:08:25We also have a lot of close
  • 01:08:27collaborations and partnerships.
  • 01:08:28As I mentioned earlier,
  • 01:08:29that was also part of our engagement
  • 01:08:31with the Yellow Culture Ambassadors,
  • 01:08:33which has been so critical because as
  • 01:08:35part of our ongoing collaborations from.
  • 01:08:37Working across government academia industry,
  • 01:08:39working with the Yellow Cultural Ambassadors,
  • 01:08:40we know that community engagement is
  • 01:08:42so important and that is one of the
  • 01:08:45strategies that can help us be successful.
  • 01:08:47And enrolling a diverse population an
  • 01:08:49as Reverend Perry in Clayton has said
  • 01:08:51and what they've also of course work
  • 01:08:54to help us educate others on is the
  • 01:08:56fact that we need to have bidirectional
  • 01:08:58engagement with the community.
  • 01:08:59We need to make sure that we have
  • 01:09:02consistent engagement with the
  • 01:09:03community and also that we are making
  • 01:09:05sure that we have long term strategies
  • 01:09:07to engage with the community.
  • 01:09:09And all of that is important in our
  • 01:09:11in our work on related to diversity
  • 01:09:13in clinical trials and one other
  • 01:09:15area that I'll just highlight.
  • 01:09:16I mentioned the fact that this is work
  • 01:09:18that we've been doing for a number of years.
  • 01:09:21Of course, also during COVID-19 and
  • 01:09:23amplifying and raising awareness.
  • 01:09:24But we also do this for other
  • 01:09:26diseases and conditions.
  • 01:09:27One of those, for example,
  • 01:09:28is Lucas.
  • 01:09:29We actually have patient listening sessions
  • 01:09:30that are coming up related to that,
  • 01:09:32so I did want to highlight that
  • 01:09:34we know that when we talk about
  • 01:09:36clinical trial diversity,
  • 01:09:37we need to think about that across
  • 01:09:39the diseases and conditions that
  • 01:09:40impact our minority communities.
  • 01:09:42Thank you teacher.
  • 01:09:43I wonder if you could share the Yale
  • 01:09:46Center for Clinical Investigation.
  • 01:09:48An insight ESA have supported a
  • 01:09:49lot of this work in increasing
  • 01:09:52inclusion in our clinical trials,
  • 01:09:54and if you could share a little bit
  • 01:09:57about that and maybe even talk about.
  • 01:10:01How? Why did YCC I start the
  • 01:10:04Cultural ambassadors program?
  • 01:10:07Thank you so much and just to echo,
  • 01:10:09were Admiral Rojo's comments.
  • 01:10:11You know, we've been thrilled
  • 01:10:13to work in this space and it
  • 01:10:15really was born out of a need.
  • 01:10:18We, like many other centers
  • 01:10:19when we started this effort,
  • 01:10:21most of our clinical trials had
  • 01:10:23very low representation of minority
  • 01:10:25populations in any of our clinical
  • 01:10:27trials and I think it was really when
  • 01:10:30we started the ambassadors program.
  • 01:10:32We we we heard from the community
  • 01:10:34that the only way we were going to
  • 01:10:37change this was to have the voice
  • 01:10:39of the Community at the table.
  • 01:10:42And so it's been wonderful to
  • 01:10:44partner with Raml Rojo and the
  • 01:10:46FDA over the past few years.
  • 01:10:48But also with Marcella with Alan with
  • 01:10:50with our our wonderful principle,
  • 01:10:52investigators like on Emma
  • 01:10:54Ann and the ambassadors.
  • 01:10:55But really, in this platform approach,
  • 01:10:57thinking about not only supporting the
  • 01:11:00ambassadors and making sure that they
  • 01:11:02have the information and that they can,
  • 01:11:04we can support what they're
  • 01:11:06trying to do in the Community.
  • 01:11:08But having them at the table at the
  • 01:11:11time when we're designing this study,
  • 01:11:13having them at the table as
  • 01:11:15we think about recr.
  • 01:11:17Admit strategies and so making
  • 01:11:18sure that our our trials are
  • 01:11:21designed in a way that actually
  • 01:11:23facilitate diverse participation.
  • 01:11:24Making sure as as Marcela already mentioned,
  • 01:11:27that we're thinking about
  • 01:11:29issues like transportation or,
  • 01:11:30as Alan mentioned,
  • 01:11:31that we're thinking about how to reach them,
  • 01:11:34whether that be through the electronic
  • 01:11:37medical record you're making.
  • 01:11:38Sure those record those those
  • 01:11:40those invitations are culturally
  • 01:11:41and linguistically appropriate,
  • 01:11:43or reaching them at a pop-up
  • 01:11:45clinic at the church and our
  • 01:11:48work did begin prior to Covanta.
  • 01:11:50I we are.
  • 01:11:53All here talking about Covid in the
  • 01:11:55spotlight that covert has shown on these
  • 01:11:58issues of of health inequity and disparity,
  • 01:12:01but it is really important.
  • 01:12:03There are lots of clinical trials we have,
  • 01:12:06you know.
  • 01:12:06Diabetes,
  • 01:12:07cardiovascular disease,
  • 01:12:07cancer, other areas.
  • 01:12:09HIV, which is the area that only Amor
  • 01:12:12works in when he's not doing this.
  • 01:12:14But I think that it's very
  • 01:12:16important to to focus and make sure
  • 01:12:19that we have awareness about the
  • 01:12:22importance of importance of diverse.
  • 01:12:24Participation across all clinical research
  • 01:12:26because that's how we'll get the answers.
  • 01:12:28That's how we'll make sure that we
  • 01:12:30know that drugs and devices are safe
  • 01:12:33and effective across populations,
  • 01:12:34and so I think that that's a those
  • 01:12:37are really important messages that
  • 01:12:39that we that we that we have been
  • 01:12:42focused on here in Connecticut,
  • 01:12:44and part of why we formed the
  • 01:12:46cultural ambassadors because we
  • 01:12:48knew that that having those voices,
  • 01:12:50those trusted voices was going to
  • 01:12:52be the way to reach the community
  • 01:12:54and make sure that they understood.
  • 01:12:57It had all other questions answered
  • 01:12:59as they considered clinical trials
  • 01:13:01participation.
  • 01:13:03Maybe I'll turn to Reverend Perry
  • 01:13:05and Reverend Clayton and Clayton
  • 01:13:07piece of talked about this importance
  • 01:13:09of a bidirectional partnership.
  • 01:13:11And I know you've been both very active
  • 01:13:14in the community and in influencing.
  • 01:13:17For example, pushing for flu vaccination
  • 01:13:19and talking about the areas where
  • 01:13:22you'd like to see more research.
  • 01:13:24I wonder if you could share your
  • 01:13:26thoughts on where you'd like to
  • 01:13:29see clinical research and what you
  • 01:13:31think would be of highest impact.
  • 01:13:41I think that one of the in terms
  • 01:13:45of our bidirectional relationship.
  • 01:13:47One of the. One of the good things is that.
  • 01:13:51Were able to say to.
  • 01:13:56Two aryel investigators NYCC I hear us.
  • 01:13:59Here are some of the things that
  • 01:14:02impact our community and we want to
  • 01:14:05focus on on these things like sickle
  • 01:14:08cell or prostate cancer or or health
  • 01:14:11breast cancer and and so then we.
  • 01:14:14We in our partnership they help us to
  • 01:14:18bring researchers and then we can talk to.
  • 01:14:21And then we can help them while
  • 01:14:23they help lead us so that when we
  • 01:14:26talk to our our people we can say,
  • 01:14:28you know, there's a study going
  • 01:14:30on or there's a possibility that
  • 01:14:32a trial may be helpful to you.
  • 01:14:34And I think that's that's that's phenomenal.
  • 01:14:37It's not 1 sided.
  • 01:14:39It's not one way,
  • 01:14:40but it's it's bidirectional and I like that.
  • 01:14:44The other thing is,
  • 01:14:45even in the structuring of what we do,
  • 01:14:47we are able to sometimes.
  • 01:14:52Push forward with our own ideas and
  • 01:14:54agendas with regards to what we
  • 01:14:57think will help get the message out.
  • 01:15:00For example, I had been stressing
  • 01:15:02for three years that we needed to
  • 01:15:05be on this black radio station and
  • 01:15:07finally we got our our our approval
  • 01:15:10so that now on on any given Monday
  • 01:15:13we can have people from Yale,
  • 01:15:16professional people, doctors,
  • 01:15:17people from IRB people who are doing
  • 01:15:21research to come on to the show.
  • 01:15:23And and meet with our community
  • 01:15:26through to the zoom session
  • 01:15:28through Facebook and radio Live.
  • 01:15:31We also have a newspaper.
  • 01:15:34So that when people look at the newspaper,
  • 01:15:37they don't see pictures of just
  • 01:15:39Caucasian people in medicine,
  • 01:15:40they see us working with K Caucasian
  • 01:15:42people and in health industry and it
  • 01:15:45makes it makes it more palatable for them
  • 01:15:47when they know that we are involved in this.
  • 01:15:50And this is, you know,
  • 01:15:52we we we are stressing,
  • 01:15:54uh, you know,
  • 01:15:55across the board we have so many
  • 01:15:57plans and you know, I really,
  • 01:15:59I really feel that if I air them
  • 01:16:02now they may have a hopeful chance.
  • 01:16:05Like a young Ambassador plan an
  • 01:16:07what I called the reparation plan,
  • 01:16:09which is to help more minorities get
  • 01:16:11involved in in the healthcare industry
  • 01:16:14starting with junior high and high school.
  • 01:16:16I think that those are things
  • 01:16:18that we're looking for sponsors
  • 01:16:20and people to help us to do,
  • 01:16:23but I think that could change the
  • 01:16:25face of medicine and the disparity
  • 01:16:27that that lag somewhere between
  • 01:16:29why we go and why we don't go to
  • 01:16:32see our primary care physician.
  • 01:16:38Urban Clayton do you have?
  • 01:16:39Do would you like to add anything?
  • 01:16:44Dream Brown I think Doctor Perry
  • 01:16:47covered that very very well,
  • 01:16:50so I did all that that those comments. OK,
  • 01:16:54Dean Brown may. May
  • 01:16:56I just address one thing
  • 01:16:59Reverend forever Perry.
  • 01:17:01So thank you, Reverend Perry,
  • 01:17:03for our listeners are cultural ambassadors
  • 01:17:06have so many wonderful ideas that it
  • 01:17:08takes me some time to catch up with them.
  • 01:17:11But we are on the radio show.
  • 01:17:13You can find all of the past
  • 01:17:16shows on the on the Cultural
  • 01:17:18Ambassadors website of the YCC I.
  • 01:17:20And you can hear actually Marcella
  • 01:17:22has done one of the shows only
  • 01:17:25ammo has done one of the shows and
  • 01:17:27Doctor Ballsack will be joining
  • 01:17:29the ambassadors on March 15th so.
  • 01:17:32We are in fact trying to keep
  • 01:17:34up and we do have a program.
  • 01:17:37The young ambassadors and it is
  • 01:17:39very much tide into some of the
  • 01:17:41pipeline initiatives that are
  • 01:17:43so very important to all of us.
  • 01:17:45And I don't know you and
  • 01:17:47marcella both have had many.
  • 01:17:48You have many plans for how we can
  • 01:17:51work on and diversify our pipeline.
  • 01:17:53If either one of you would like to join
  • 01:17:56me in helping Reverend Perry tonight.
  • 01:18:02Will you please to help? I pledge to help.
  • 01:18:06In your spare time, so Marcella you.
  • 01:18:10Your research interest is HealthEquity,
  • 01:18:12and I'm wondering if you could comment
  • 01:18:15on whether code the kovid pandemic has
  • 01:18:18changed the way you think about that.
  • 01:18:24Thank you, I appreciate that
  • 01:18:26opportunity to reflect on that.
  • 01:18:28You know, I think. Anne.
  • 01:18:32You know some of the things we've
  • 01:18:34been talking about tonight have
  • 01:18:36are sort of core principles and
  • 01:18:39values for HealthEquity research,
  • 01:18:41and you know this is a field that
  • 01:18:43has evolved even some in my my couple
  • 01:18:46decades here where we've moved from
  • 01:18:49talking about health disparities.
  • 01:18:51Sort of observing and cataloguing
  • 01:18:54differences to talking about HealthEquity
  • 01:18:56and health justice and using a very
  • 01:18:58social justice framework to think about.
  • 01:19:01How we've gotten to where we are.
  • 01:19:04Sort of systematic denial of access to
  • 01:19:06opportunity and resources for certain
  • 01:19:08groups and communities in our country,
  • 01:19:10and helps us to think about
  • 01:19:12how we solution find,
  • 01:19:14which is where we should be.
  • 01:19:17Not admiring the problem,
  • 01:19:18but intervening on it and doing so in
  • 01:19:21deep partnership in the ways we've been
  • 01:19:24talking about in a bidirectional way.
  • 01:19:26Showing up with the expertise
  • 01:19:28that we bring from academia.
  • 01:19:29Recognizing that's not all the expertise
  • 01:19:32needed to solve to solve for an equity,
  • 01:19:34so you know,
  • 01:19:36I think what thinking ahead to the work.
  • 01:19:40What is perhaps promising is the collective.
  • 01:19:43Now having really insights into in equities,
  • 01:19:46having conversations and spaces
  • 01:19:48in places that are overdue.
  • 01:19:50But I think people are showing up
  • 01:19:54in earnest to think about how do
  • 01:19:57we move forward. It is just key.
  • 01:20:00That coming out,
  • 01:20:02building resilience into our recovery
  • 01:20:04that we are incredibly intentional about,
  • 01:20:06making sure that we are disrupting
  • 01:20:08the patterns that have been
  • 01:20:10so predictable for so long,
  • 01:20:12which communities will be hit the hardest.
  • 01:20:14And so I think that is one of the
  • 01:20:17hopes and promises for COVID-19 moving
  • 01:20:19forward is that we will no longer,
  • 01:20:22for those of us who are HealthEquity
  • 01:20:26researchers.
  • 01:20:26We so many of us have just said,
  • 01:20:29well,
  • 01:20:29we are sadly not surprised and
  • 01:20:31really just to disrupt that moving
  • 01:20:32forward is absolutely key.
  • 01:20:36Great. It's it's a. It's been
  • 01:20:39a very fast hour and a half.
  • 01:20:42We have about 9 minutes left and what I
  • 01:20:45would like to do with those 9 minutes
  • 01:20:47is just give each of our panelists the
  • 01:20:50opportunity to make any last comment.
  • 01:20:52So Doctor bosses Akal start with you.
  • 01:21:03Tom, are you?
  • 01:21:08I was inviting panelists. I froze OK.
  • 01:21:13Arzum world yes. Well, connectivity at
  • 01:21:15home is not sometimes the best.
  • 01:21:19I'm sorry I missed it
  • 01:21:20'cause I was frozed. Yes.
  • 01:21:22Well I'm inviting we have just
  • 01:21:24a few minutes left and I wanted
  • 01:21:26to give everybody a chance
  • 01:21:28to make any last comments.
  • 01:21:29If you would like to say anything
  • 01:21:31more about the system's response
  • 01:21:33to cobit or the vaccination
  • 01:21:35program 833, ask why NHH.
  • 01:21:37If you're going to sign up for vaccine,
  • 01:21:39we gotta get that number out there.
  • 01:21:42We're going to be doing a lot more
  • 01:21:44pop up vaccines across Bridgeport,
  • 01:21:46New London and of course New Haven.
  • 01:21:49You know these conversations
  • 01:21:50are so important to get.
  • 01:21:52I love the term Marcelo was using.
  • 01:21:54Say that again, it's not hesitancy.
  • 01:21:57It's vaccine, confidence, confidence.
  • 01:21:58I love the way you flipped it around an.
  • 01:22:01I think that you know combination of
  • 01:22:03access and confidence will get us there.
  • 01:22:06So in these conversations,
  • 01:22:07get all of us smarter every
  • 01:22:09time we have them.
  • 01:22:12Alan
  • 01:22:14thank you Tim Brown.
  • 01:22:15So I think you know for us just
  • 01:22:18it's been a pleasure working with
  • 01:22:20culture ambassadors and I think
  • 01:22:21teaching myself and others just,
  • 01:22:23you know, understand that technology
  • 01:22:24is not going to solve everything,
  • 01:22:26but we certainly wanted to help you know.
  • 01:22:29Bridge any devise as much as
  • 01:22:31possible and welcome you know
  • 01:22:32ideas and novel solutions and we're
  • 01:22:34happy to brainstorm with you.
  • 01:22:36Know one of those and continue working
  • 01:22:38with the culture ambassadors to do so.
  • 01:22:41Great. Onyema
  • 01:22:46yeah, so just reflecting back at COVID-19,
  • 01:22:49I think that it's been great to see the
  • 01:22:52success is that can be achieved with
  • 01:22:55collaboration and I think just listening
  • 01:22:57in on the call from you know those
  • 01:23:00involved in regulatory those in thinking
  • 01:23:02about HealthEquity bringing IT solutions.
  • 01:23:04You know system solutions to addressing
  • 01:23:06disease, an developing, malleable
  • 01:23:08systems that can adapt to and improvise.
  • 01:23:10And you know just it's just amazing.
  • 01:23:13And I hope things don't end with covid.
  • 01:23:16I hope that. Some of the things
  • 01:23:18that we plan we carry on with us.
  • 01:23:21I also think that COVID-19 just
  • 01:23:23following up on the question,
  • 01:23:25Dean Brownie asked Marcela,
  • 01:23:26I think that you know some of these
  • 01:23:29inequities have existed and COVID-19
  • 01:23:30has just blown it wide open and I
  • 01:23:33think it's been an eye opener for
  • 01:23:35people who were probably previously
  • 01:23:36blind or not fully appreciative of,
  • 01:23:38you know some of those issues
  • 01:23:40and I hope that you know these
  • 01:23:42opportunities that have been created.
  • 01:23:44We can, you know, address them,
  • 01:23:46head on and hopefully make some headway.
  • 01:23:48In the future addressing these huge problems.
  • 01:23:52Thank you, Marcela.
  • 01:23:56Thank you, I'm just again so grateful to have
  • 01:23:59been in this conversation and cannot resist.
  • 01:24:01But to bring the public health message,
  • 01:24:03we are so very close we're on the
  • 01:24:05cusp of increased supply for vaccine,
  • 01:24:07so I'm asking everyone just to recommit for
  • 01:24:09a little bit longer to all the things that
  • 01:24:12we know will work to keep ourselves safe,
  • 01:24:14our family safe,
  • 01:24:15our community safe, you know.
  • 01:24:17I say the mask is my friend.
  • 01:24:19Please wear your mask right?
  • 01:24:20If you were living in a multi
  • 01:24:22generational home or people who are
  • 01:24:24at risk and you were out and about.
  • 01:24:26You can wear a mask at home.
  • 01:24:28We do it here in my family, right?
  • 01:24:30The social distancing on the hand washing
  • 01:24:32just a little bit longer right now is
  • 01:24:34not the time to let down our guard.
  • 01:24:36Please please please.
  • 01:24:37We were so close to being able to
  • 01:24:39have enough vaccine supply for
  • 01:24:41all of the adults in the country,
  • 01:24:43so just a little bit longer.
  • 01:24:44Thank you, thank you, thank you.
  • 01:24:47Thank you.
  • 01:24:49Amral
  • 01:24:54I'm also when I say you know,
  • 01:24:56huge thank you for the opportunity
  • 01:24:58to participate in discussion tonight
  • 01:25:00and I'm going to use my last moments
  • 01:25:02of my last kind of input to answer a
  • 01:25:05question that actually came in and said,
  • 01:25:07what resources does your office have for
  • 01:25:09diverse communities related to the vaccine?
  • 01:25:11So I did want to highlight that we
  • 01:25:13just recently released two videos
  • 01:25:15that talk about the importance
  • 01:25:17of vaccination for communities.
  • 01:25:18You can find that on FPS YouTube page.
  • 01:25:21Of course, I just want to echo
  • 01:25:23what Doctor Nunez.
  • 01:25:24Smith just mentioned vaccines or
  • 01:25:26one of the safest tools to prevent
  • 01:25:28infectious diseases like COVID-19.
  • 01:25:29It's so important to protect you
  • 01:25:31and your loved ones from the virus,
  • 01:25:34so also, you know,
  • 01:25:35emphasizing the point of mask,
  • 01:25:36wearing,
  • 01:25:37hand washing and social distancing
  • 01:25:38because it's so important.
  • 01:25:40And I did also want to close out
  • 01:25:42with one other on resource that
  • 01:25:44I think is just really helpful.
  • 01:25:46I mentioned are sent for
  • 01:25:48biologics evaluation and research.
  • 01:25:49They are our experts related to
  • 01:25:51vaccines and doctor Peter Marks
  • 01:25:53the director for that center.
  • 01:25:55Just held a webinar with our
  • 01:25:57office last week.
  • 01:25:58It was an hour long webinar where he
  • 01:26:00talked about what diverse communities
  • 01:26:02need to know about the chobit 19
  • 01:26:04vaccines so we will make sure that
  • 01:26:06all of those that are participating
  • 01:26:08tonight have those resources.
  • 01:26:09Thank you, thank you and
  • 01:26:11our hosts for this evening.
  • 01:26:12Let me start with Reverend Perry.
  • 01:26:19I would simply say that.
  • 01:26:23In in this darkness,
  • 01:26:25we've come together and that.
  • 01:26:28God is somehow giving us a light.
  • 01:26:32And that's good news,
  • 01:26:34because you can't say that
  • 01:26:36he did not provide us with.
  • 01:26:38A solution to this situation.
  • 01:26:41So science and faith have come together
  • 01:26:44and we March in hand in hand to victory.
  • 01:26:47And that's my sermon.
  • 01:26:49And I'm not gonna ask for an offering.
  • 01:26:52But that's the sermon we have.
  • 01:26:54We have. We have 3 three vaccines and
  • 01:26:57three is the biblical number for us,
  • 01:27:00and so we just urging everyone to
  • 01:27:02to take this vaccine to trust.
  • 01:27:05In this pandemic,
  • 01:27:06the best solution that all of our
  • 01:27:09great minds have come up with an.
  • 01:27:11I just think this panel for
  • 01:27:13helping our communities and other
  • 01:27:15communities get a better understanding
  • 01:27:17and a better grip on what this.
  • 01:27:20This pandemic has done and is doing to
  • 01:27:22us and how we can address it and look at it.
  • 01:27:25Thank you Reverend Clayton.
  • 01:27:30Thank you Dean Brown.
  • 01:27:33Faith without works. Is dead.
  • 01:27:38So we pray now that we will
  • 01:27:41go to work and we hope that.
  • 01:27:44Those that were on the
  • 01:27:47zoom call tonight will.
  • 01:27:50Who were on the fence in terms of
  • 01:27:52taking their or getting the vaccine,
  • 01:27:54which would jump on board
  • 01:27:56because the vaccine is safe?
  • 01:27:58Effective and it save lives.
  • 01:28:05Thank you, and last, I'd like
  • 01:28:07to turn this to Keisha Harris,
  • 01:28:10who organized this evening's seminar
  • 01:28:12and ask you for your last words.
  • 01:28:17So I'm I'm going to take the
  • 01:28:19podium for for like Rear Admiral,
  • 01:28:22Rojo and Marcella did to make
  • 01:28:24our clinical trials play that.
  • 01:28:26It's been really important to have
  • 01:28:29people like us in the vaccine trials
  • 01:28:31and people like us did participate.
  • 01:28:34This was a trial that included
  • 01:28:36people who had type 2 diabetes,
  • 01:28:38people who had high blood
  • 01:28:40pressure and so many others,
  • 01:28:42and I think it's really important
  • 01:28:45to just celebrate the success.
  • 01:28:47Here in Connecticut we know our own site.
  • 01:28:50We were able to have 41% of our participants
  • 01:28:53be from under represented populations,
  • 01:28:55but we want to have that achievement
  • 01:28:57across the board an even higher
  • 01:29:00greater so that we really understand
  • 01:29:02those issues of health and equity.
  • 01:29:04We understand those issues as
  • 01:29:06it relates to the therapeutics
  • 01:29:08and the medicines that we have.
  • 01:29:10An aswer Admiral Rojo says that
  • 01:29:12we really we need to carry these
  • 01:29:14important lessons that we've learned
  • 01:29:16from Kovit but take them into all
  • 01:29:19of other the other diseases in
  • 01:29:21the other fights that we have,
  • 01:29:23because we need to make sure that we
  • 01:29:25have treatments in all of these areas
  • 01:29:28where we have a disproportionate impact
  • 01:29:30on the on our black and Brown populations,
  • 01:29:32and and so it's really just so
  • 01:29:35important for us to think about that.
  • 01:29:37It's also very important that are black
  • 01:29:40and Brown communities that we still
  • 01:29:42seek health care and that we take care
  • 01:29:44of our diabetes in our hypertension.
  • 01:29:46And all of those other.
  • 01:29:48Comorbidities that we have during covette
  • 01:29:50and it is safe and so I just want to
  • 01:29:53make sure that everyone understands that
  • 01:29:54and then just on a programming note.
  • 01:29:57I know that there have been
  • 01:29:59a lot of questions tonight.
  • 01:30:01A lot of links we had.
  • 01:30:03I think I maybe 30 or so questions
  • 01:30:05that were pre submitted so we will
  • 01:30:08be posting this video on our way CCI
  • 01:30:11website with the rest of the town
  • 01:30:13halls that have been conducted by
  • 01:30:15our health system and our partners.
  • 01:30:17We will also be posting all of the links,
  • 01:30:20many of which have been posted in the chat,
  • 01:30:23but we will be providing links to those
  • 01:30:26resources that have been referenced
  • 01:30:28tonight and thank you very much.
  • 01:30:30Jean Brown for.
  • 01:30:31Moderating this session tonight
  • 01:30:33and keeping all of us
  • 01:30:34moving. Thank you so much.
  • 01:30:36Thanks to all of our panelists.
  • 01:30:38Goodnight goodnight.